{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:49:42Z","timestamp":1790880582162,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41409-020-0929-y","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T10:05:00Z","timestamp":1589537100000},"page":"2170-2179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed\/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT"],"prefix":"10.1038","volume":"55","author":[{"given":"Anna","family":"Sureda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-9984","authenticated-orcid":false,"given":"Sonja","family":"Genadieva Stavrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Boumendil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Finel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Khvedelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Dietricht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chara","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry C.","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"929_CR1","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","volume":"327","author":"GP Canellos","year":"1992","unstructured":"Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478\u201382.","journal-title":"N Engl J Med"},{"key":"929_CR2","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet. 1993;341:1050\u20134.","journal-title":"Lancet"},{"key":"929_CR3","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high dose chemotherapy with autologous haematopoietic stem cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u2013207.","journal-title":"Lancet"},{"key":"929_CR4","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","volume":"54","author":"RF Duarte","year":"2019","unstructured":"Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transpl. 2019;54:1525\u201352.","journal-title":"Bone Marrow Transpl"},{"key":"929_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"A Sureda","year":"2012","unstructured":"Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study\u2014a prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/Trasplante de M\u00e9dula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97:310\u20137.","journal-title":"Haematologica"},{"key":"929_CR6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3324\/haematol.13441","volume":"94","author":"SP Robinson","year":"2009","unstructured":"Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin\u2019s lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94:230\u20138.","journal-title":"Haematologica"},{"key":"929_CR7","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/S0140-6736(05)66659-7","volume":"365","author":"KS Peggs","year":"2005","unstructured":"Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, et al. Clinical evidence of a graft\u2010versus\u2010Hodgkin\u2019s\u2010lymphoma effect after reduced\u2010intensity allogeneic transplantation. Lancet. 2005;365:1934\u201341.","journal-title":"Lancet"},{"key":"929_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","volume":"12","author":"I Alvarez","year":"2006","unstructured":"Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006;12:172\u201383.","journal-title":"Biol Blood Marrow Transplant"},{"key":"929_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3324\/haematol.11828","volume":"93","author":"P Anderlini","year":"2008","unstructured":"Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, et al. Fludarabine\u2010melphalan as a preparative regimen for reduced\u2010intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin\u2019s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008;93:257\u201364.","journal-title":"Haematologica"},{"key":"929_CR10","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.bbmt.2016.03.028","volume":"22","author":"P Anderlini","year":"2016","unstructured":"Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, et al. Gemcitabine, fludarabine, and melphalan for reduced-intensity conditioning and allogeneic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2016;22:1333\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"929_CR11","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","volume":"115","author":"B Sarina","year":"2010","unstructured":"Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, et al. Allogeneic transplantation improves the overall and progression free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115:3671\u20137.","journal-title":"Blood"},{"key":"929_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(96)90536-X","volume":"347","author":"N Schmitz","year":"1996","unstructured":"Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347:353\u20137.","journal-title":"Lancet"},{"key":"929_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/sj.bmt.1701941","volume":"24","author":"R Kanteti","year":"1999","unstructured":"Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, et al. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease: a clinical and molecular analysis. Bone Marrow Transpl. 1999;24:473\u201381.","journal-title":"Bone Marrow Transpl"},{"key":"929_CR14","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.2001.19.5.1395","volume":"19","author":"A Sureda","year":"2001","unstructured":"Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garc\u00eda-Conde J, et al. Autologous stem-cell transplantation for Hodgkin\u2019s disease: results and prognostic factors in 494 patients from the Grupo Espa\u00f1ol de Linfomas\/Transplante Aut\u00f3logo de M\u00e9dula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19:1395\u2013404.","journal-title":"J Clin Oncol"},{"key":"929_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","volume":"26","author":"A Sureda","year":"2008","unstructured":"Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455\u201362.","journal-title":"J Clin Oncol"},{"key":"929_CR16","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1093\/annonc\/mdw421","volume":"27","author":"S Genadieva-Stavrik","year":"2016","unstructured":"Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed\/refractory Hodgkin\u2019s lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol. 2016;27:2251\u20137.","journal-title":"Ann Oncol"},{"key":"929_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/bmt.2016.349","volume":"52","author":"J Gauthier","year":"2017","unstructured":"Gauthier J, Castagna L, Garnier F, Guillaume T, Soci\u00e9 G, Maury S, et al. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transpl. 2017;52:689\u201396.","journal-title":"Bone Marrow Transpl"},{"key":"929_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bbmt.2017.11.030","volume":"24","author":"J Mariotti","year":"2018","unstructured":"Mariotti J, Devillier R, Bramanti S, Giordano L, Sarina B, Furst S, et al. T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with hla-identical related donors. Biol Blood Marrow Transplant. 2018;24:627\u201332.","journal-title":"Biol Blood Marrow Transplant"},{"key":"929_CR19","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"C Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2017;35:3425\u201332.","journal-title":"J Clin Oncol"},{"key":"929_CR20","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","volume":"125","author":"AK Gopal","year":"2015","unstructured":"Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:1236\u201343.","journal-title":"Blood"},{"key":"929_CR21","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. Programmed death\u20101 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34:3733\u20139.","journal-title":"J Clin Oncol"},{"key":"929_CR22","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36:1428\u201339.","journal-title":"J Clin Oncol"},{"key":"929_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"929_CR24","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"929_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295\u2013304.","journal-title":"Transplantation"},{"key":"929_CR26","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/leu.2011.230","volume":"26","author":"TH Terwey","year":"2012","unstructured":"Terwey TH, Vega-Ruiz A, Hemmati PG, Martus P, Dietz E, le Coutre P, et al. NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemia. Leukemia. 2012;26:536\u201342.","journal-title":"Leukemia."},{"key":"929_CR27","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/bmt.2016.20","volume":"51","author":"JR Passweg","year":"2016","unstructured":"Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic stem cell transplantation in Europe 2014; more than 40000 transplants annually. Bone Marrow Transpl. 2016;51:786\u201392.","journal-title":"Bone Marrow Transpl"},{"key":"929_CR28","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa022473","volume":"348","author":"V Diehl","year":"2003","unstructured":"Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP\/ABVD for advanced Hodgkin\u2019s disease. N Engl J Med. 2003;348:2386\u201395.","journal-title":"N Engl J Med"},{"key":"929_CR29","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/bmt.2013.51","volume":"48","author":"JR Passweg","year":"2013","unstructured":"Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte RF, et al. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transpl. 2013;48:1161\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"929_CR30","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853\u201362.","journal-title":"Lancet"},{"key":"929_CR31","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","volume":"14","author":"N Milpied","year":"1996","unstructured":"Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin\u2019s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996;14:1291\u20136.","journal-title":"J Clin Oncol"},{"key":"929_CR32","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1182\/bloodadvances.2019001016","volume":"3","author":"E Das-Gupta","year":"2019","unstructured":"Das-Gupta E, Thomson KJ, Bloor AJC, Clark AD, Mackinnon S, Kayani I, et al. Allo-HSCT in transplant-na\u00efve patients with Hodgkin lymphoma: a single-arm, multicenter study. Blood Adv. 2019;3:4264\u201370.","journal-title":"Blood Adv"},{"key":"929_CR33","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/bmt.2016.357","volume":"52","author":"L Hegerova","year":"2017","unstructured":"Hegerova L, Cao Q, Lazaryan A, McClune BL, Weisdorf DJ, Brunstein CG, Bachanova V, et al. Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. Bone Marrow Transpl. 2017;52:697\u2013703.","journal-title":"Bone Marrow Transpl"},{"key":"929_CR34","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.bbmt.2014.06.037","volume":"20","author":"R Chen","year":"2014","unstructured":"Chen R, Palmer JM, Tsai NC, Thomas SH, Siddiqi T, Popplewell L, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20:1864\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"929_CR35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjh.15152","volume":"181","author":"A Bazarbachi","year":"2018","unstructured":"Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, et al. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. Br J Haematol. 2018;181:86\u201396.","journal-title":"Br J Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0929-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0929-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-020-0929-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:18:18Z","timestamp":1684617498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-0929-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["929"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-0929-y","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]},"assertion":[{"value":"21 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}